<DOC>
	<DOCNO>NCT00517920</DOCNO>
	<brief_summary>Phase 2 Study ABT-869 Advanced Hepatocellular Carcinoma ( HCC )</brief_summary>
	<brief_title>Phase 2 Study ABT-869 Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>An Open-label , Phase 2 study efficacy tolerability ABT-869 advance hepatocellular carcinoma ( HCC )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion Criteria Subject must great equal 18 year age Subject must diagnose unresectable metastatic HCC Subjects must measurable lesion RECIST CT scan least one site receive radiation Subject Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 No active malignancy within past 5 year Exclusion Criteria Subject receive targeted VEGF/PDGF/TKI therapy . Prior Avastin allow Subject ChildPugh grade Class C hepatic impairment The subject proteinuria Common Toxicity Criteria ( CTC ) grade &gt; 1 measure routine urinalysis 24 hour urine collection screen assessment Subject currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure &gt; 100 mmHg systolic blood pressure &gt; 150 mmHg . Subjects may rescreened blood pressure show control without intervention The subject document leave ventricular Ejection Fraction &lt; 50 % Subject receive therapeutic anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>